Literature DB >> 17895528

Poly(ADP-Ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite.

Tamás Radovits1, Julia Zotkina, Li-Ni Lin, Timo Bömicke, Rawa Arif, Domokos Gerö, Eszter M Horváth, Matthias Karck, Csaba Szabó, Gábor Szabó.   

Abstract

Reactive oxygen species, such as myeloperoxidase-derived hypochlorite, induce oxidative stress and DNA injury. The subsequent activation of the DNA-damage-poly(ADP-ribose) polymerase (PARP) pathway has been implicated in the pathogenesis of various diseases, including ischemia-reperfusion injury, circulatory shock, diabetic complications, and atherosclerosis. We investigated the effect of PARP inhibition on the impaired endothelium-dependent vasorelaxation induced by hypochlorite. In organ bath experiments for isometric tension, we investigated the endothelium-dependent and endothelium-independent vasorelaxation of isolated rat aortic rings using cumulative concentrations of acetylcholine and sodium nitro-prusside. Endothelial dysfunction was induced by exposing rings to hypochlorite (100-400 microM). In the treatment group, rings were preincubated with the PARP inhibitor INO-1001. DNA strand breaks were assessed by the TUNEL method. Immunohistochemistry was performed for 4-hydroxynonenal (a marker of lipid peroxidation), nitrotyrosine (a marker of nitrosative stress), and poly(ADP-ribose) (an enzymatic product of PARP). Exposure to hypochlorite resulted in a dose-dependent impairment of endothelium-dependent vasorelaxation of aortic rings, which was significantly improved by PARP inhibition, whereas the endothelium-independent vasorelaxation remained unaffected. In the hypochlorite groups we found increased DNA breakage, lipidperoxidation, and enhanced nitrotyrosine formation. The hypochloride-induced activation of PARP was prevented by INO-1001. Our results demonstrate that PARP activation contributes to the pathogenesis of hypochlorite-induced endothelial dysfunction, which can be prevented by PARP inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17895528     DOI: 10.3181/0701-RM-16

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  4 in total

1.  Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.

Authors:  Sevil Korkmaz-Icöz; Bartosz Szczesny; Michela Marcatti; Shiliang Li; Mihály Ruppert; Felix Lasitschka; Sivakkanan Loganathan; Csaba Szabó; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-10-02       Impact factor: 8.739

Review 2.  Targeting vascular (endothelial) dysfunction.

Authors:  Andreas Daiber; Sebastian Steven; Alina Weber; Vladimir V Shuvaev; Vladimir R Muzykantov; Ismail Laher; Huige Li; Santiago Lamas; Thomas Münzel
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

3.  Endothelial dysfunction of bypass graft: direct comparison of in vitro and in vivo models of ischemia-reperfusion injury.

Authors:  Gábor Veres; Péter Hegedűs; Enikő Barnucz; Raphael Zöller; Stephanie Klein; Harald Schmidt; Tamás Radovits; Sevil Korkmaz; Matthias Karck; Gábor Szabó
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

4.  Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury?

Authors:  Peter Onody; Rita Stangl; Andras Fulop; Oliver Rosero; David Garbaisz; Zsolt Turoczi; Gabor Lotz; Zoltan Rakonczay; Zsolt Balla; Viktor Hegedus; Laszlo Harsanyi; Attila Szijarto
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.